Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

17p cytogenetic changes in TP53-mutated AML

View Full Paper
Ask AI
Bookmark
Share

Authors

SSSharon SanthoshASAdit SinghalJKJonathan E. Kolitz

Discussion

Loading...

Member takes

Overview

Analysis reveals chromosomal abnormalities in acute myeloid leukemia with TP53 mutations, suggesting implications for survival outcomes.

Key Points

  • 90 patients with TP53-mutated AML were evaluated, revealing frequent chromosomal abnormalities but no survival benefit.
  • The most common chromosomal abnormality was del(17), found in 52.5% of cases with structural changes involving 17p.
  • Survival analysis using log-rank testing showed no significant differences among TP53 mutation types in overall survival outcomes.
  • Findings may call for deeper exploration of genomic instability processes as potential therapeutic targets in AML.

Cite This Study

Santhosh et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236da39https://doi.org/10.1182/blood-2025-3506
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 117p loss in TP53-non-mutated myeloid neoplasms confers survival comparable to TP53-mutated disease2025
  2. 2Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report2025 · 2 citations
  3. 3CPX-351 is a feasible bridge to allogeneic hematopoietic stem cell transplantation in TP53 mutated acute myeloid leukemia with myelodisplastic related changes or therapy related without del(17p): Sub-analysis from a large italian real world retrospective study2025
  4. 4Characteristics and prognostic implications of TP53 mutations in Chinese patients with myelodysplastic syndromes2025 · 3 citations
  5. 5TP53 and PPM1D mutations in AML: Distinct frequencies, shared pathway, and adverse prognostic trends2025